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Human HCF-1 (also referred to as HCFC-1) is a transcriptional co-regulator that undergoes
a complex maturation process involving extensiveO-GlcNAcylation and site-specific pro-
teolysis. HCF-1 proteolysis results in two active, noncovalently associated HCF-1N and
HCF-1C subunits that regulate distinct phases of the cell-division cycle. HCF-1 O-GlcNAcy-
lation and site-specific proteolysis are both catalyzed by O-GlcNAc transferase (OGT),
which thus displays an unusual dual enzymatic activity. OGT cleaves HCF-1 at six highly
conserved 26 amino acid repeat sequences called HCF-1PRO repeats. Here we character-
ize the substrate requirements for OGT cleavage of HCF-1. We show that the HCF-1PRO-
repeat cleavage signal possesses particular OGT-binding properties. The glutamate resi-
due at the cleavage site that is intimately involved in the cleavage reaction specifically inhib-
its association with OGT and its bound cofactor UDP-GlcNAc. Further, we identify a novel
OGT-binding sequence nearby the first HCF-1PRO-repeat cleavage signal that enhances
cleavage. These results demonstrate that distinct OGT-binding sites in HCF-1 promote pro-
teolysis, and provide novel insights into the mechanism of this unusual protease activity.
Introduction
Post-translational modifications can alter protein functions and thus greatly enhance the diver-
sity of gene function. There are two principal types of post-translational protein modifications:
proteolysis, which is essentially irreversible, and attachment of a chemical group—such as gly-
cosylation studied here—which is often reversible.
One of the most abundant forms of glycosylation in eukaryotic organisms is the addition of
N-acetylglucosamine (GlcNAc) to serines or threonines of nuclear and cytoplasmic proteins, giv-
ing rise to O-linked β-N-acetylglucosamine (O-GlcNAc) proteins [1]. The enzyme catalyzing this
modification is the highly conserved glycosyltransferaseO-linked β-N-acetylglucosamine trans-
ferase (OGT), which uses the sugar donor UDP-GlcNAc as cofactor. UDP-GlcNAc is the end
product of the hexosamine biosynthetic pathway, a nutrient-sensing pathway, andO-GlcNAcyla-
tion has thus been proposed to reflect cellular nutrient levels [2, 3].O-GlcNAcylation can affect
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protein phosphorylation [4], enzymatic activity [5], protein stability [6], specific protein-protein
interactions [7] or protein aggregation [8]. We have recently shown that OGT also possesses an
unexpected proteolytic activity towards the human host-cell factor 1 (HCF-1) [9].
HCF-1 is a transcriptional co-regulator that is not only cleaved [9], but also O-GlcNAcy-
lated [10–12] by OGT. After synthesis as a 2035 amino acid precursor protein, HCF-1 under-
goes a maturation process involving O-GlcNAcylation of the N-terminal half of the protein [9,
12] and site-specific proteolysis, resulting in a set of N- (HCF-1N) and C- (HCF-1C) terminal
subunits [9, 10, 13, 14]. After processing, the HCF-1N and HCF-1C subunits remain tightly, but
noncovalently associated [13–15] and regulate distinct phases of the cell-division cycle [16].
HCF-1N promotes G1-to-S-phase transition [16] via association with E2F transcription factors
[17, 18] and Thap11 [19], and HCF-1C promotes proper M-phase progression [16]. OGT-
mediated HCF-1 proteolytic processing ensures proper cell-cycle progression through activa-
tion of HCF-1C-subunit M-phase functions [9].
HCF-1 proteolysis occurs at six centrally located and highly conserved repeated sequences
called HCF-1PRO repeats. Each HCF-1PRO repeat contains 26 amino acids with a conserved 20
amino acid core sequence shared among vertebrate species, but not in invertebrate species [9,
10, 14]. The HCF-1PRO repeat forms an unusually large protease recognition sequence [9, 13],
displaying a bipartite sequence architecture: a “cleavage region” containing a critical glutamate
residue at the site of cleavage and a “threonine region” containing a number of highly con-
served threonine residues.
The structure of human OGT is also bipartite with an N-terminal superhelical 13.5 tetratri-
copeptide-repeat (TPR) domain [20] followed by a globular catalytic domain, which contains
the UDP-GlcNAc binding pocket [21]. A crystal structure of human OGT containing 4.5 TPRs
in complex with an HCF-1PRO repeat and a non-hydrolysable form of UDP-GlcNAc [22] has
revealed that the bipartite structures of OGT and of the HCF-1PRO repeat interact with each
other in a complementary manner. The HCF-1PRO-repeat threonine region binds stably to the
OGT TPR domain through a network of hydrogen bonds connecting the HCF-1PRO-repeat
threonine side-chains and backbones with OGT, whereas the HCF-1PRO-repeat cleavage region
binds to the OGT catalytic domain, analogous to an O-GlcNAcylation substrate [22]. How the
OGT catalytic domain, UDP-GlcNAc and the HCF-1PRO repeat promote proteolysis is not
understood. Interestingly, the E10 cleavage-site residue forms an N-terminal pyroglutamate
after cleavage in vitro that probably represents a product of the cleavage reaction [22]. Lazarus
et al. [22] proposed that the cofactor UDP-GlcNAc plays a pivotal role for cleavage, because (i)
it is located in close proximity to the E10 side-chain at the cleavage site, and (ii) it is strictly
required for HCF-1PRO-repeat proteolysis.
In the present study, we analyze HCF-1–OGT interactions that promote proteolysis. We
probe how the HCF-1PRO repeat interacts with OGT and UDP-GlcNAc and thus extend our
understanding of the cleavage mechanism. Furthermore, we identify a novel OGT-binding
sequence nearby the first HCF-1PRO repeat that enhances HCF-1PRO-repeat cleavage. Thus,
multiple distinct OGT-binding sites in HCF-1 promote HCF-1 cleavage.
Results
The glutamate residue at the HCF-1PRO-repeat cleavage site displays an
unfavorable binding behavior to OGT
Previous in vivo and in vitro cleavage studies of the HCF-1PRO repeat embedded in a heterolo-
gous context (i.e., the Oct-1 transcription factor) have shown that the activities of the cleavage
and threonine regions are sensitive to alanine substitutions [9, 13]. To probe the role of
HCF-1PRO-repeat residues for cleavage in their natural sequence environment, we used a
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recombinant cleavage substrate called HCF-1rep1 [9]. Fig 1A illustrates the structure of human
HCF-1 with the six HCF-1PRO repeats shown in yellow. The HCF-1rep1 substrate, shown
below the full-length HCF-1 structure, contains the first HCF-1PRO repeat embedded into its
HCF-1 context. We performed in vitro cleavage assays with bacterially purified human OGT
and HCF-1rep1 substrates with residues surrounding the cleavage site (P7-T14) mutated to
alanine. The results (S1A Fig) paralleled those of the previous Oct-1/HCF-1 hybrid studies [9,
13], although the HCF-1PRO-repeat residues T11, H12, and E13 exhibited little importance in
this assay, leading us to refine the HCF-1PRO-repeat cleavage region to the sequence encom-
passing residues P7 to E10, as shown in Fig 1A.
In vivo co-immunoprecipitation assays have shown that the replacement of the E10 residue
by alanine (E10A) enhances HCF-1–OGT association [9]. To characterize this and other inter-
actions between the HCF-1PRO-repeat cleavage region and the OGT catalytic domain, we first
estimated the individual side-chain contributions to OGT binding for residues P7 to T14,
using the molecular mechanics–generalized born surface area (MM-GBSA) approach [23, 24].
For this purpose, we used the HCF-1PRO-repeat–OGT crystal structure (PDB code 4N3B [22])
and replaced the E10Q glutamine residue in the HCF-1PRO repeat of that structure by gluta-
mate and UDP-5SGlcNAc (a non-hydrolysable cofactor used for structure determination [22,
25]) by UDP-GlcNAc. We note that the configurations of the glutamate (E10) in the replace-
ment in silico structure and the glutamine (E10Q) side-chains in the complex are nearly identi-
cal [22]. These computational calculations predicted that the E10 residue is indeed unusual
within the cleavage region: it is the only residue between P7 and T14 to display highly unfavor-
able interactions with OGT complexed with UDP-GlcNAc (Fig 1B). In contrast, T14 of the
threonine region and P7 and C9 of the cleavage region display favorable OGT-binding contri-
butions and, consistent with the aforementioned cleavage assay (S1A Fig), the intervening resi-
dues (T11–E13) exhibit minor or no contributions to OGT binding.
To support the results obtained by the molecular dynamics approach, we tested the individ-
ual P7 to T14 HCF-1PRO-repeat alanine mutants in an in vitroHCF-1rep1–OGT binding assay
in the presence of UDP-GlcNAc, as described [22]. Mutant HCF-1rep1 binding to OGT was
quantified and normalized to wild-type HCF-1rep1 binding (Fig 1C) from an immunoblot
analysis shown in S1B Fig. Consistent with the molecular dynamics results, only the E10A
mutation caused a considerable increase in HCF-1rep1 binding with respect to wild-type (Fig
1C). Because other point mutations, such as P8A and C9A inhibit proteolysis (S1A Fig), but do
not promote OGT binding, the increase in OGT affinity of the E10A mutant is not simply
explained by an inhibition of proteolysis of the binding substrate. Thus, physical interaction
assays, as well as computational analyses indicate that E10 possesses unfavorable interactions
in the OGT–UDP-GlcNAc–HCF-1PRO-repeat complex.
E10 side-chain incompatibility in the OGT–UDP-GlcNAc–HCF-1PRO-
repeat complex
The observation that E10 is the only residue that we tested in the HCF-1PRO repeat that inter-
feres with binding to OGT and is positioned near the sugar moiety of UDP-GlcNAc in the crys-
tal structure [22] led us to ask whether this E10 property is dependent on the presence of
UDP-GlcNAc. For this purpose, we performed in vitro binding assays with a set of HCF-1rep1
mutants containing E10 substitutions (E10A, E10Q, E10D, and E10S) that have been described
to inhibit HCF-1PRO-repeat cleavage [22]. The E10S mutant not only inhibits cleavage like
E10A, E10Q, and E10D, but also provides an active substrate for HCF-1PRO-repeat O-GlcNA-
cylation [22]. Fig 1D shows HCF-1rep1–OGT binding in the presence (lanes 1–7) or absence
(lanes 8–14) of UDP-GlcNAc. As previously described [22], in the presence of UDP-GlcNAc,
HCF-1 Cleavage by OGT
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the wild-type E10 substrate displayed reduced OGT binding (Fig 1D, lane 2), whereas the
E10A substrate displayed enhanced OGT binding (lane 4). Similarly to the E10A mutant, the
E10D and E10Q mutants (lanes 5 and 6) enhanced binding to OGT, in spite of the structural
similarities between the glutamate, glutamine, and aspartate side-chains. The E10S O-GlcNA-
cylation substrate enhanced OGT binding (lane 7) like the E10A, E10Q, and E10D mutants.
Thus, replacement of E10 by either similar (E10Q and E10D) or unlike (E10A and E10S) resi-
dues increased OGT binding. The threonine region T17–22A mutant contains four grouped
threonine to alanine substitutions and was shown to inhibit binding to the OGT TPR domain
[22]. As previously described [22], in the presence of UDP-GlcNAc, the T17–22A mutant dis-
played reduced OGT binding (lane 3).
When UDP-GlcNAc was omitted from the assay, however, binding of the E10 missense
mutants was not noticeably altered (lanes 11–14), whereas binding of the substrates containing
E10 in their HCF-1PRO repeats (WT and T17–22A) increased considerably (Fig 1D, compare
lanes 9 and 10 to lanes 2 and 3). These results suggest that UDP-GlcNAc exhibits a negative
effect on binding of the HCF-1PRO-repeat E10 residue in the OGT active site and that this effect
is highly dependent on the glutamate structure. The inhibitory effect also depends on the sugar
moiety of UDP-GlcNAc, as with UDP alone, the E10A mutant did not enhance OGT associa-
tion (S1C Fig).
To determine the role of the E10 side-chain for interactions with the OGT–UDP-GlcNAc
complex, we estimated the OGT-binding contributions of E10, E10A, E10D, and E10Q resi-
dues in the presence or absence of UDP-GlcNAc using molecular modeling, as described
above. In this analysis (Fig 1E), in the presence of UDP-GlcNAc, the wild-type E10 residue dis-
played the most unfavorable OGT interaction among the tested residues, as indicated by the
positive value for the contribution to the binding free-energy (ΔGbind). E10D displayed a more
favorable OGT interaction, albeit still inhibitory, presumably because of the similarly nega-
tively charged aspartate side-chain. The neutral side-chains of E10A and E10Q both displayed
favorable interactions with OGT. When UDP-GlcNAc was omitted from the OGT active site
in the molecular dynamics simulations, the contributions to the binding free-energy of the
unfavorable E10 and E10D contacts decreased, suggesting that the removal of UDP-GlcNAc
can release strains in the complex, consistent with the in vitro binding assays (Figs 1C, 1D, and
S1C). We conclude that the inhibitory effect of the E10 side-chain is most prominent in the
presence of UDP-GlcNAc. Thus, not only HCF-1PRO-repeat proteolysis but also HCF-1PRO-
Fig 1. The glutamate residue at position 10 in the HCF-1PRO repeat inhibits OGT binding. (A) (Top) Schematic representation of the human HCF-1
protein showing the six HCF-1PRO repeats as yellow triangles. (Bottom) Schematic of the recombinant HCF-1rep1 precursor (HCF-1 residues 867–1071),
containing the HCF-1PRO repeat 1 (rep1) and surrounding sequences fused to glutathione-S-transferase (GST). The 26 residues of rep1 are shown and the
site of proteolysis is marked at the C/E sequence by a black arrowhead. The 20 amino acid core sequence [14] is shaded gray, and the cleavage and
threonine regions are indicated. (B) E10 exhibits inhibitory contributions to OGT binding. Computational estimation of the contributions to the binding free-
energy, ΔGbind, of single amino acid residues in the HCF-1PRO repeat (P7-T14) for the association with OGT. Negative and positive values correspond to
favorable and unfavorable OGT-association contributions, respectively, in the in silico structural complex (based on the 4N3B structure [22]). (C) An E10 to
alanine substitution enhances HCF-1PRO-repeat–OGT binding. In vitro HCF-1rep1–OGT binding assay in the presence of UDP-GlcNAc with HCF-1rep1
constructs containing individual alanine substitutions in the HCF-1PRO repeat (P7A-T14A). HCF-1rep1 binding to OGT was quantified from an immunoblot
(S1B Fig) as ratio of OGT-bound HCF-1rep1 to total HCF-1rep1 in the assay. Obtained values are presented as log2 fold change relative to wild-type HCF-
1rep1–OGT binding. (D) HCF-1PRO-repeat–OGT binding is influenced by the E10 side-chain properties and exhibits sensitivity to UDP-GlcNAc. In vitro HCF-
1rep1–OGT binding assay. Constructs with wild-type (WT), E10 missense mutations (E10A, E10D, E10Q, and E10S), and T17-T22Amutations were
incubated in the presence (left panel) or absence (right panel) of UDP-GlcNAc. Detection of OGT and HCF-1rep1 was performed using the indicated
antibodies. *, IgG heavy chain. (E) Computational estimation of the contributions to the binding free-energy, ΔGbind, of single amino acid residues at the E10
cleavage site for the association with OGT. Shown are residue contributions of WT (E10), alanine (E10A), aspartate (E10D) or glutamine (E10Q) side-chains
in the presence or absence of UDP-GlcNAc in the in silico structural complex (based on the 4N3B structure). (F) Close-up view (4N3C crystal structure [22])
of the OGT active site with the HCF-1PRO repeat and UDP-GlcNAc. The deprotonated E10 oxygen atom exhibits an unfavorable interaction with OGT. (G)
Snapshot from a molecular dynamics simulation (based on the 4N3B structure) of the OGT active site in complex with the HCF-1PRO repeat without
UDP-GlcNAc. The displayed frame is representative of the average distances sampled along the simulations. In (F) and (G), the E10 side-chain is shown in
ball and stick representation (carbons: gray, nitrogen: blue, oxygens: red), and dashed lines indicate distances between atoms.
doi:10.1371/journal.pone.0136636.g001
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repeat–OGT association is influenced by the E10 side-chain structure and UDP-GlcNAc—per-
haps this specific type of HCF-1PRO repeat and OGT association promotes cleavage.
To understand the E10 interaction better, we examined the location of the HCF-1PRO-repeat
E10 side-chain and UDP-GlcNAc in the OGT active site of the crystal structure (PDB code
4N3C [22]). Consistent with the above-described results, we noticed that the E10 side-chain is
located in close proximity (2.8 Å) of the carbonyl oxygen of glycine 654 in the OGT catalytic
domain, potentially causing an unfavorable electrostatic repulsion (Fig 1F). The E10 carboxylate
functional group is maintained in this unfavorable position by the glucose moiety of UDP-Glc-
NAc. When we performed a molecular dynamics simulation without UDP-GlcNAc (representa-
tive snapshot along the trajectory shown in Fig 1G), the E10 residue can change its position to
prevent the unfavorable interaction with glycine 654 and appears to form a favorable interaction
with a nitrogen atom in the imidazole ring of histidine 498 in the OGT catalytic domain.
Together, these results suggest that UDP-GlcNAc inhibits HCF-1PRO-repeat–OGT associa-
tion by imposing that the E10 side-chain be in an unfavorable position within the complex.
This incompatibility may cause strains in the OGT–UDP-GlcNAc–HCF-1PRO-repeat complex,
which, we hypothesize, initiates or facilitates HCF-1PRO-repeat proteolysis. We thus propose
that the mechanism of OGT-mediated HCF-1 proteolysis involves strains originating from the
cleavage substrate.
Sequences lying outside of the HCF-1PRO repeat promote proteolysis
Unexpectedly, in previous experiments, a single HCF-1PRO repeat was not sufficient for
OGT-mediated proteolysis (Capotosti and Herr, unpublished results). As the HCF-1rep1 sub-
strate (Fig 1A) was cleaved, we asked what sequences outside of the HCF-1PRO repeat in this
construct might be promoting cleavage. For this purpose, we divided the residues upstream of
HCF-1PRO repeat 1 into three regions (Fig 2A): Region I, comprising identified O-GlcNAcyla-
tion sites [9], and Region II and Region III, which contain nearly the same number of residues,
58 and 60, respectively. We note that the sequences of these three regions are conserved in
vertebrate species (S2A Fig; [26]), where HCF-1 cleavage is meditated by OGT, but not in
invertebrate species, where HCF cleavage is mediated by Taspase1 [27]. We generated deletion
constructs (schematics in S2B Fig) containing only one of the three Regions I-III (referred to as
+I, +II, and +III), lacking only one of the three regions (referred to as ΔI, ΔII, and ΔIII) or lack-
ing all three regions together (called ΔI.II.III). The E10A mutation in ΔI.II.III/E10A served as a
negative control for cleavage.
In a 48-hour in vivo transient transfection HCF-1rep1 cleavage assay (Fig 2A), the absence
of all three regions together lowered HCF-1PRO-repeat cleavage efficiency when the ratios
between cleaved product and total of uncleaved and cleaved products of each construct were
compared (Fig 2A, lanes 1–3). Among the three regions, the lack of Region II had the strongest
negative effect on cleavage (lanes 4–6). The addition of Regions I, II, and III individually
enhanced HCF-1PRO-repeat cleavage (lanes 7–9) with respect to the ΔI.II.III construct (lane 2),
with Region II, offering the greatest enhancement and Region III promoting minimal enhance-
ment. This in vivoHCF-1 cleavage assay displayed variability among independent experiments,
particularly in reference to the ΔI.II.III and ΔIII constructs (S2C Fig), most likely owing to the
difficulty in controlling in vivo synthesis rates and stability of the different constructs via the
transient transfection assay. Nevertheless, these results led us to conclude that, although all
three regions display cleavage-enhancement activity, Region II has the most pronounced activ-
ity on HCF-1PRO-repeat proteolysis.
HCF-1 Cleavage by OGT
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An HCF-1 cleavage enhancer element (CEE) promotes efficient HCF-
1PRO-repeat proteolysis
To solidify the aforementioned conclusion concerning the in vivo cleavage studies, we per-
formed in vitro cleavage assays under controlled conditions with bacterially synthesized pro-
teins and determined the rates of cleavage of a subset of HCF-1rep1 constructs in an eight-
hour time course. The rate of cleavage for the ΔI.II.III construct was substantially lower than
for the full-length (FL) construct (Fig 2B). Relative to these activities, the FL and +II HCF-
1rep1 constructs displayed similarly enhanced activities, whereas the +III and ΔI.II.III con-
structs displayed similarly reduced activities. The difference between the two groups was
particularly evident at the earlier time points, i.e., after 1 and 2 hours. Together with the in vivo
studies above, these results indicate a robust role for Region II in HCF-1PRO-repeat cleavage
enhancement.
To probe the sequence dependence of the activity of Region II on cleavage, we replaced the
wild-type sequence in construct +II by a scrambled Region II sequence (+II_scrambled). As
shown in Fig 2C, in a 4-hour in vitro cleavage assay, +II_scrambled (lanes 5 and 6) showed little
cleavage activity when compared to the wild-type +II construct (lanes 3 and 4), indeed no
more activity than a Region II construct with an inactive HCF-1PRO repeat (+II_T17–22A)
(lanes 7 and 8). This result suggests that the specific amino acid sequence of Region II plays a
role in the enhancement of HCF-1PRO-repeat cleavage.
In previous studies, HCF-1PRO-repeat cleavage was assayed when the repeat was embedded
within the C-terminal region of the Oct-1 POU transcription factor [9, 13]. When, however,
embedded within the flexible linker [28] connecting the two structured domains of the Oct-1
POU DNA-binding domain (construct POUrep2, Fig 2D), the HCF-1PRO repeat was inactive
(Capotosti and Herr, unpublished results). To test whether Region II can reactivate the
POUrep2 substrate, we inserted either Region II (construct +II-POUrep2) or Region III (+III-
POUrep2) upstream of the inactive HCF-1PRO repeat. As shown in a 48-hour in vivo cleavage
assay (Fig 2D), the POUrep2 construct (lane 2) displayed little, if any, cleavage activity. Region
III weakly enhanced HCF-1PRO-repeat cleavage (lane 3), whereas Region II enhanced cleavage
more effectively (lane 4). Thus, Region II is a sequence-specific enhancer of HCF-1PRO-repeat
cleavage. We therefore refer to this sequence as a Region II HCF-1PRO-repeat cleavage
enhancer element or Region II CEE.
Fig 2. HCF-1PRO-repeat cleavage enhancement by a sequence nearby the HCF-1PRO repeat 1. (A) HCF-
1PRO-repeat cleavage is context dependent in vivo. (Top) Schematic of the HCF-1rep1 precursor subdivided
into Region I (25 residues, blue), Region II (58 residues, pink), and Region III (60 residues, gray). (Bottom)
HEK 293 cells were transfected with expression vectors encoding HCF-1rep1 FL or deletion constructs,
either containing or lacking Regions I, II or III. Proteins were immunoprecipitated by an N-terminal HA-tag and
assayed for cleavage by visualization by α-HA-tag immunoblot. *, C-terminal precursor truncations. (B)
Region II enhances HCF-1PRO-repeat cleavage in vitro. Cleavage efficiency during an in vitro cleavage assay
time course of selected HCF-1rep1 constructs. HCF-1rep1 constructs were incubated with OGT for 0 to 8 h
and precursor and resulting N-terminal cleavage products were analyzed for cleavage by α-GST-
immunoblot. Uncleaved and cleaved products were quantified and cleavage efficiencies determined as
cleaved products over total. Shown are the means and standard deviations of three independent
experiments. (C) Region II cleavage-enhancement activity is sequence specific. In vitro cleavage assay of
HCF-1rep1 FL and Region II constructs containing a scrambled Region II sequence (+II_scrambled) or an
inactive HCF-1PRO repeat (+II_T17–22A). Resulting precursor and N-terminal cleavage products were
analyzed for cleavage with the indicated antibodies. (D) Region II activates the inactive POUrep2 construct
for cleavage. (Left) Schematic of the GST-fusion construct POUrep2 containing HCF-1PRO repeat 2 (rep2),
embedded in between the POU-specific (POUS) and POU-homeo domains (POUH) of Oct-1. Region II or
Region III were inserted N-terminal of rep2, respectively. (Right) In vivo cleavage activities in HEK 293 cells,
transiently transfected with transfection medium (mock) or POUrep2 encoding plasmids. Precursors and
cleaved fragments were purified via immunoprecipitation of an N-terminal HA-tag and cleavage assayed
using the indicated antibody. In (A), (C) and (D), prominent (●) and faint (○) cleavage products are indicated.
doi:10.1371/journal.pone.0136636.g002
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The Region II CEE is a novel OGT-binding sequence
As the Region II CEE influences HCF-1PRO-repeat cleavage in a sequence-dependent manner,
we asked whether it represents a sequence-specific binding site for OGT. Fig 3A (panel a)
shows HCF-1rep1 binding in an OGT-directed pull-down assay with a set of mutant HCF-
1rep1 substrates. Because of the inhibitory role of E10 for OGT binding, full-length wild-type
HCF-1rep1 (Fig 3A, FL, lane 2) bound more weakly to OGT than the E10A mutant (E10A,
lane 3). The ΔI.II.III construct displayed weak OGT association (lane 4), correlating with its
low cleavage efficiency, whereas, relative to the +I and +III constructs, the +II construct bound
strongly to OGT (compare lane 6 to lanes 5 and 7), correlating with the cleavage activities of
these constructs. These results suggest that the Region II CEE contains an OGT-binding site.
As the HCF-1PRO repeat itself represents an OGT-binding site, we investigated whether the
Region II CEE can bind OGT independently of the HCF-1PRO repeat and whether the binding
mode is similar. To test this in an in vitroHCF-1rep1–OGT binding assay, we employed two
strategies. First, we assayed wild-type OGT binding (Fig 3B, lanes 1–5) to a set of HCF-1
constructs: a +II HCF-1rep1 construct defective for HCF-1PRO-repeat–OGT interactions
(i.e., +II_T17–22A), or constructs with Region II (wild-type or scrambled) or Region III alone
(i.e., II_alone, II_scramb_alone, or III_alone). The constructs containing the Region II wild-
type sequences clearly associated with WT OGT (Fig 3B, lanes 2 and 3), showing that Region II
can associate with OGT independently of the HCF-1PRO repeat. Curiously, although the scram-
bled Region II sequence did not enhance HCF-1PRO-repeat proteolysis (Fig 2C), it did bind to
OGT (Fig 3B, lane 4), suggesting that OGT–Region II binding possesses relaxed sequence
dependency. Nevertheless, OGT–Region II binding is clearly not entirely sequence indepen-
dent, as the Region III sequence did not bind efficiently to OGT (lane 5).
In the second strategy, we probed whether the OGT TPR domain is involved in OGT–
Region II binding. For this purpose, we used the HCF-1 cleavage and O-GlcNAcylation com-
promised 5N-5A OGT mutant, which disrupts HCF-1PRO-repeat–OGT association [22]. The
results show (Fig 3B, lanes 6–10) that the OGT TPR domain is important for OGT binding of
the Region II sequences, suggesting a role of the OGT TPR domain in Region II recognition
and binding.
We conclude that OGT binds autonomously to the Region II CEE, representing an indepen-
dent OGT-binding site. Furthermore, OGT–Region II interactions are mediated by the OGT
TPR domain, showing that the TPRs not only recognize the threonine region, but also other
HCF-1 sequences lying outside of the HCF-1PRO repeat.
The Region II CEE contains a cluster ofO-GlcNAcylation sites
HCF-1 is a highly O-GlcNAcylated protein and O-GlcNAcylation sites, predominantly in the
HCF-1N subunit, have been identified in several studies [9, 12, 29, 30]. To identify potential O-
GlcNAcylation sites in the Region II CEE, we performed liquid chromatography followed by
tandem mass spectrometry (LC-MS/MS). O-GlcNAcylation sites in an HCF-1 precursor con-
struct (residues 686 to 1166) spanning the HCF-1 residues contained in the HCF-1rep1 con-
struct have been described [9], but the HCF-1 sequences covering Region II were not included,
because the peptides generated by combined trypsin and Glu-C digestion of this region were
not appropriate for LC-MS/MS analysis [9]. Thus, O-GlcNAcylation sites were identified
in Region I, but could not be in Region II and a part of Region III. To overcome the lack of pep-
tide coverage in the Region II and III sequences for LC-MS/MS analysis, we engineered two
trypsin cleavage sites by site-directed mutagenesis at two different positions within the HCF-1
sequence (A933K and M951K). The mutations had no effect on HCF-1rep1 cleavage and over-
all O-GlcNAcylation levels, as determined by immunoblot (S3A Fig).
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Fig 3. The Region II CEE represents an OGT-binding sequence. (A) Region II enhances OGT–HCF-1rep1 binding. Full-length (FL) and deletion HCF-
1rep1 constructs were tested for OGT binding in the presence of UDP-GlcNAc using an in vitroOGT-directed pull-down assay. Detection of OGT and HCF-
1rep1 was performed, using the indicated antibodies. Shown are 100% of OGT pull-down (panels a and b) and 11% of the input (panels c and d). *, IgG
heavy chain. (B) HCF-1PRO-repeat-independent OGT–Region II binding. (Left) Schematics of the HCF-1 constructs used in this experiment. (Right) HCF-
1rep1 containing Region II and an OGT-binding defective HCF-1PRO repeat (+II_T17–22A), or GST-fusion constructs containing Region II (wild-type or
scrambled) alone or Region III alone (II_alone, II_scramb_alone, III_alone) were tested for binding with wild-type (WT) (left panel) or 5N-5A mutant (right
panel) OGT. HCF-1 binding was detected as in (A). In (A) and (B), weak (○) and effective (●) OGT binding is indicated.
doi:10.1371/journal.pone.0136636.g003
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We purified full-length HCF-1rep1 with the engineered trypsin cleavage sites after transient
synthesis in HEK 293 cells and analyzed the uncleaved precursor band (Fig 4A, band a), as well
as the N-terminal cleavage product (band b) for O-GlcNAcylation. The identified O-GlcNAcy-
lation sites of the HCF-1rep1 precursor and the N-terminal cleavage product were nearly iden-
tical (S1 Table), suggesting that HCF-1rep1 O-GlcNAcylation has minor effects on proteolysis
and vice-versa. Fig 4A illustrates schematically the results of the O-GlcNAcylation analysis of
the HCF-1rep1 uncleaved precursor protein. Because of the new trypsin cleavage sites, full pep-
tide coverage of the HCF-1 sequence was achieved. Previously identified confident O-GlcNA-
cylation sites (red squares) in Region I [9] were confirmed. A cluster of four novel confident
(red squares) and two novel potential (blue squares) O-GlcNAcylation sites in the Region II
CEE, and one novel confident and two novel potential O-GlcNAcylation sites in Region III
were identified. Thus, in summary, we conclude that the Region II CEE (i) enhances HCF-
1PRO-repeat cleavage, (ii) associates efficiently with OGT, and (iii) contains a cluster of O-
GlcNAcylated serines and threonines.
Since HCF-1 is phosphorylated [31, 32, 33] and interference between O-GlcNAcylation and
phosphorylation in the same protein has been demonstrated in previous studies (reviewed in
[4]), we also searched for phosphorylation sites in the LC-MS/MS analysis (Fig 4A, yellow cir-
cles). We thus confirmed a previously mapped phosphorylation site in Region III at S984 [a
potential glycogen synthase kinase-3 (GSK-3) phosphorylation site; [30]] and identified a
novel phosphorylation site at S1070 in the less-well conserved sequence C-terminal of the
HCF-1PRO repeat. In an in vivo cleavage assay, both an alanine substitution of S984 to inhibit
phosphorylation and an aspartate substitution of S984 to constitutively mimic phosphorylation
did not alter O-GlcNAcylation levels or cleavage efficiencies of the HCF-1rep1 substrates, as
detected by immunoblot (S3B Fig). These results indicate that phosphorylation of S984 in
Region III interferes neither with HCF-1PRO-repeat cleavage nor HCF-1rep1 O-GlcNAcylation.
Curiously, however, whereas we detected phosphorylation of S984 in the HCF-1rep1 precursor
and cleaved products, we only detected S984 O-GlcNAcylation in the cleaved product (S1
Table). We have not investigated further a potential relationship between S984 O-GlcNAcyla-
tion and HCF-1PRO-repeat cleavage.
Region II CEEO-GlcNAcylation is not affected by HCF-1PRO-repeat
proteolysis
It has been suggested that inhibition of HCF-1PRO-repeat proteolysis by E10A mutations in the
HCF-1PRO repeat decreases general HCF-1 O-GlcNAcylation levels [9, 12]. Thus, we investi-
gated whether Region II O-GlcNAcylation is affected by E10A (or related mutations) inhibition
of proteolysis. For this purpose, we assessed the in vivo O-GlcNAcylation levels of a representa-
tive Region II CEE peptide by LC-MS/MS (peptide sequence underlined below the diagram in
Fig 4A, HCF-1 sequence 901–933). This analysis showed that the HCF-1 901–933 peptide con-
tains 0, 1, 2 or 3 O-GlcNAcylation sites, showing that under the conditions of our assay, this
HCF-1 sequence is modified sub-stoichiometrically. The HCF-1 901–933 peptides were either
derived from wild-type (WT), or from the cleavage inactive E10A, E10D, E10Q, and E10S
HCF-1rep1 mutants which, while inhibiting proteolysis, enhance HCF-1PRO-repeat–OGT
binding (see Fig 1D and 1E). The proportions of HCF-1 901–933 peptides with the different
stoichiometries of O-GlcNAcylated forms were assessed (Fig 4B). Cleavage inactive mutants
containing the E10 mutations (E10A, E10D, E10Q, and E10S) displayed decreased HCF-1
901–933 O-GlcNAcylation levels when compared to peptides derived fromWT precursor or
cleaved N-terminal proteins (Fig 4B).
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We also analyzed Region II peptides derived from the T17–22A mutant that inhibits cleav-
age through a defective HCF-1pro-repeat–OGT TPR domain interaction [22]. To our surprise,
HCF-1 901–933 peptides derived from this mutant displayed nearly identicalO-GlcNAcylation
levels in comparison with peptides derived fromWT HCF-1rep1 (Fig 4B). This result suggests
that OGT binding to the HCF-1PRO repeat is not required for O-GlcNAcylation of HCF-1
sequences. Furthermore, the decreased O-GlcNAcylation levels observed in the HCF-1rep1
E10 mutants are specific to mutations at the E10 cleavage site and not to the inhibition of cleav-
age per se. To support these results, we deleted the entire HCF-1PRO repeat in the HCF-1rep1
construct to obtain a mutant called HCF-1rep1 ΔPRO, and found nearly identical O-GlcNAcy-
lation levels when compared to WT and T17–22A HCF-1rep1 (Fig 4B). Thus, the E10 missense
mutants have a dominant repressive effect on Region II O-GlcNAcylation, perhaps by trapping
and sequestering OGT at the uncleavable mutant E10 HCF-1PRO repeat. We observed the same
repressive effect in an LC-MS/MS analysis of peptides derived from Region I (data not shown),
indicating that this effect is not confined to Region II.
The Region II CEE enhances HCF-1PRO-repeat cleavage independently
of itsO-GlcNAcylation status
It has been proposed that HCF-1 O-GlcNAcylation and site-specific proteolysis influence each
other [12]. As HCF-1PRO-repeat cleavage did not influence Region II peptide O-GlcNAcylation
levels, we investigated conversely, whether HCF-1PRO-repeat proteolysis could be influenced by
Region II CEEO-GlcNAcylation. To address this question, we tested HCF-1PRO-repeat proteoly-
sis by an OGTmutant that retains its ability to cleave HCF-1rep1, but is compromised for its O-
GlcNAcylation activity (D554H_H558DOGT; Kapuria and Herr, unpublished results). We com-
pared cleavage andO-GlcNAcylation activities of WT and D554H_H558D OGT on HCF-1rep1
FL or +II and +III substrates (Fig 4C). Cleavage efficiencies of substrates cleaved byWTOGT or
by D554H_H558D OGT were nearly identical (Fig 4C, upper panel, lanes 2, 3, 5, 6, 8, and 9).
Importantly, whereas O-GlcNAcylation was detected in the HCF-1rep1 FL and +II construct
when cleaved byWTOGT (lanes 2 and 5, middle panel), highly reduced O-GlcNAcylation was
observed when cleaved by the D554H_H558Dmutant (lanes 3 and 6, middle panel), showing
that efficient HCF-1PRO-repeat cleavage can occur in the absence of prominent HCF-1rep1 O-
GlcNAcylation. These results suggest that the Region II CEE enhances HCF-1PRO-repeat cleavage
independently of its O-GlcNAcylation status. Indeed, HCF-1O-GlcNAcylation may not in fact
directly influence site-specific proteolysis of HCF-1; the cross-talk detected between HCF-1
Fig 4. Region II CEEO-GlcNAcylation and HCF-1PRO-repeat proteolysis are independent OGT activities. (A) (Left) The full-length (FL) HCF-1rep1
precursor (band a) and the N-terminal cleavage product (band b) were purified from HEK 293 lysates via α-HA-epitope immunoprecipitation and visualized by
Coomassie staining. The bands were analyzed forO-GlcNAcylation and phosphorylation sites by LC-MS/MS. (Right) Schematic representation of identified
HCF-1rep1O-GlcNAcylation (squares) and phosphorylation (yellow circles) sites in the uncleaved HCF-1rep1 precursor. The HCF-1 sequences covered by
the analysis (residues 867–1071) and the engineered trypsin cleavage sites A933K and M951K are indicated below the diagram. Red and blue squares
indicate confident (Mascot score > 23 & probability of localization > 70%) and potential (Mascot score 14–22 or probability of localization 50–70%)O-
GlcNAcylation sites, respectively. Squares surrounded in black indicate previously identified sites [9]. The HCF-1 Region II CEE amino acid sequence
spanning a peptide sequence used in subsequent analyses (underlined: 901–933K) is shown below the diagram.(B) Analysis of a representative Region II
CEE peptide (901–933K sequence shown in A) by LC-MS/MS for proportions of differentO-GlcNAcylated forms. The proportions of 901–933K peptides
containing 0, 1, 2 or 3 attachedO-GlcNAc moieties are given for each sample in percent. HCF-1rep1 constructs were synthesized in HEK 293 cells and
peptides were derived from constructs containing wild-type (WT) or mutated (E10A, E10D, E10Q, E10S, T17–22A) HCF-1PRO repeats, or containing a
deletion of the HCF-1PRO-repeat sequence (ΔPRO). The results with WT precursor, E10A, and E10S were confirmed in a second independent experiment.
(C) HCF-1rep1O-GlcNAcylation is not fundamental for HCF-1PRO-repeat cleavage. In vitro cleavage activities of wild-type OGT (WT) and anO-
GlcNAcylation compromised OGTmutant (D554H_H558D) on selected HCF-1rep1 substrates. Cleavage andO-GlcNAcylation activities of constructs
containing the full-length HCF-1rep1 sequence (FL), or the Region II CEE (+II) or Region III (+III) sequences were analyzed by immunoblot using the
indicated antibodies. We note that the lack of the OGT D554H_H558DO-GlcNAcylation activity results in differential mobility of the HCF-1rep1 cleavage
products during electrophoresis. Prominent (●) and faint (○) cleavage products are indicated.
doi:10.1371/journal.pone.0136636.g004
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O-GlcNAcylation and proteolysis [12] may have simply resulted from the fact that the same
enzyme is responsible for both activities.
Discussion
We have investigated HCF-1–OGT interactions that promote HCF-1PRO-repeat proteolysis
and characterized two main aspects: the OGT interaction (i) with the HCF-1PRO repeat 1 and
(ii) with a 58 amino acid sequence lying N-terminal of HCF-1PRO repeat 1 called Region II,
which represents a cleavage enhancer element referred to here as a CEE.
The HCF-1PRO-repeat E10 cleavage-site residue strains the substrate in
the OGT active site
The HCF-1pro-repeat cleavage region binds in the OGT catalytic domain and forms a binding
interface with the nucleotide sugar UDP-GlcNAc [22], but extensive interactions via hydrogen
bonds with residues in the OGT catalytic domain have not been identified. We have shown
that the amino acid side-chain of the glutamate at position 10 of the HCF-1PRO repeat (E10),
surprisingly, exhibits a highly unfavorable interaction with the OGT–UDP-GlcNAc complex,
and is in fact the only residue in the HCF-1PRO-repeat cleavage region to display this behavior.
The OGT–HCF-1PRO-repeat binding mode is unusual for protease-substrate binding, as such
interactions commonly require complementarity between the protease active site and the
sequence surrounding the scissile bond [34]. We hypothesize that, here, the energy involved in
binding E10 is used to promote HCF-1PRO-repeat cleavage. Whereas the wild-type cleavage
region causes strains in the OGT–UDP-GlcNAc–HCF-1PRO-repeat complex, the threonine
region favors HCF-1PRO-repeat–OGT association, presumably to ensure proper accommoda-
tion of the cleavage region within the OGT catalytic domain. Perhaps the mechanism of HCF-
1 cleavage by OGT can involve substrate strains in the OGT active site, because of the large
stabilizing effect of the TPR–threonine region interaction. If true, this fact could explain the
need for a very large amino acid signal for proteolysis.
Enzymatic mechanisms involving substrate strains in catalysis have been previously
described for bacterial carbon-carbon lyases [35]. These enzymes catalyze the hydrolytic cleav-
age of either one of the amino acids tryptophan and tyrosine, using substrate strains to increase
substrate specificity and catalytic efficiency [35]. Interestingly, the substrate strains originating
from the E10 residue in the HCF-1PRO-repeat cleavage region are dependent on the sugar moi-
ety of UDP-GlcNAc, indicating that HCF-1 proteolysis is coupled to UDP-GlcNAc availability
and maybe indirectly to the cellular nutrient status. Future studies will be needed to understand
the mechanisms by which substrate strains in the HCF-1PRO-repeat cleavage region contribute
to HCF-1 proteolysis.
A CEE OGT-binding site enhances HCF-1PRO-repeat cleavage
HCF-1PRO-repeat proteolysis is a slow reaction compared to other proteolytic reactions. For
instance, complete casein digestion by trypsin occurs in the range of minutes [36]. In contrast,
maximum HCF-1PRO-repeat cleavage efficiency (approximately 50%) is reached only after
eight hours of incubation with OGT. HCF-1PRO-repeat cleavage is even less efficient in the
absence of sequences N-terminal of the HCF-1PRO repeat 1 (Regions I, II, and III). As the
HCF-1PRO repeat itself, by consisting of 26 amino acids, already represents a large protease rec-
ognition sequence, we did not expect additional requirements for efficient proteolysis.
The Region II CEE, a sequence rich in serines and threonines, displays prominent
sequence-specific HCF-1PRO-repeat cleavage-enhancement activity, which correlates to differ-
ing extents with efficient O-GlcNAcylation and OGT-binding activities. Whereas it is known
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that, for example, with Hepatitis C virus, protease activities can be stimulated by so-called
cofactor domains of the same protease protein [37], with HCF-1PRO-repeat cleavage, a protein
sequence derived from the substrate surprisingly stimulates protease activity. We note with
interest that, within the gene encoding HCF-1, the Region II CEE lies on one exon and the six
HCF-1PRO repeats lie on a separate adjacent exon (see S2A Fig)—perhaps during vertebrate
evolution the sequences encoding the Region II CEE and HCF-1PRO repeats were juxtaposed in
such a manner as to promote appropriate HCF-1-protein maturation.
Currently, there is no evidence for structured protein domains in the HCF-1 Regions I, II,
and III defined here (unpublished observations). In fact, these sequences are predicted to be
highly unstructured and could form extensive loops, such that the Region II CEE could, via a
loop, approach the first HCF-1PRO repeat. The Region II CEE might thus cause enrichment of
OGT at the HCF-1PRO repeat 1 and thereby promote cleavage, perhaps because individual
HCF-1PRO repeats do not represent effective OGT-binding sequences.
As the Region II CEE did not display sequence specificity for OGT binding in our Region
II_scrambled construct, it is possible that OGT preferentially associates with serine/threonine-
rich sequences like Region II without high specificity. Our studies indicate that the OGT TPRs
are involved in Region II CEE recognition, but we speculate that OGT–CEE-type binding is
distinct from the OGT–HCF-1PRO-repeat binding mode, because the latter displays extraordi-
narily high specificity [22]. Structural biology studies addressing the OGT–Region II CEE bind-
ing mode could shed light on the mechanisms of OGT target recognition, as well as on HCF-
1PRO-repeat cleavage enhancement. Additionally, it will be of interest to determine whether
other CEEs exist in HCF-1 and what physiological roles they might have in HCF-1 regulation
of cell-cycle progression.
HCF-1O-GlcNAcylation and proteolysis are independent OGT activities
O-GlcNAcylation can be influenced by other post-translational protein modifications, such as
phosphorylation or ubiquitylation [4, 38–41]. It has been proposed that there is cross-talk
between HCF-1 O-GlcNAcylation and proteolysis during HCF-1 maturation [12]. In this case,
a change in HCF-1PRO-repeat cleavage efficiency should cause changes in HCF-1 O-GlcNAcy-
lation levels and vice-versa. We thus hypothesized that Region II CEE O-GlcNAcylation could
be involved in its cleavage-enhancement activity, and initiated proteomic studies of the sub-
strate, i.e. in vivo post-translationally modified HCF-1 proteins, accompanied by in vitro analy-
ses, using an O-GlcNAcylation compromised OGT mutant (D554H_H558D). Contrary to
expectations, HCF-1 O-GlcNAcylation and HCF-1PRO-repeat proteolysis appear to be two
independent OGT activities.
Capotosti et al. [9] reported HCF-1PRO-repeat-dependent O-GlcNAcylation of HCF-1,
based on the finding that a series of E10A mutations in the HCF-1PRO repeats decrease overall
HCF-1 O-GlcNAcylation levels. Here we have shown, using mass spectrometry analyses, that
O-GlcNAcylation levels of HCF-1 sequences, encompassing the Region II CEE, are not depen-
dent on the presence of the HCF-1PRO repeat. We have further shown that E10 mutations in
the HCF-1PRO repeat cause enhancement of OGT–HCF-1PRO-repeat association and a reduc-
tion of O-GlcNAcylation of HCF-1 sequences upstream of the first HCF-1PRO repeat. We thus
hypothesize that an E10-mutated HCF-1PRO repeat traps OGT to its HCF-1PRO-repeat binding
site and consequently reduces OGT association to the other OGT binding-sites of the HCF-1
protein.
If Region II CEE O-GlcNAcylation does not impact HCF-1PRO-repeat proteolysis, then why
is this sequence extensively O-GlcNAcylated? O-GlcNAcylation can occur co-translationally
[42], and it was proposed that the modification could stabilize highly unstructured protein
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domains, such as the HCF-1 Basic Region and Regions I, II, and III, during and/or after transla-
tion. Moreover, O-GlcNAcylation has been implicated in the prevention of protein aggregation
[8]. Intriguingly, HCF-1 is synthesized as a long precursor protein that might require stabiliza-
tion of its unstructured regions, particularly before it is able to form stable HCF-1N–HCF-1C
subunit association [15]. Further studies addressing the role of O-GlcNAcylation for
HCF-1 protein stability and integrity could elucidate the functional outcome of HCF-1 O-
GlcNAcylation.
The finding that OGT, well known for its role in protein O-GlcNAcylation, could also repre-
sent a protease for HCF-1 maturation [9] was unexpected. Here, we have probed the properties
of HCF-1 cleavage by OGT and uncovered two novel findings pertaining to the protease activi-
ties. In the first case, the target for proteolysis—the E10 glutamate residue—specifically strains
the binding of the HCF-1PRO repeat to OGT. In the second case, an auxiliary sequence—the
Region II CEE—enhances proteolysis. Given the unusual nature of OGT cleavage of HCF-1,




The bacterial expression plasmid pGEX-HCF-1rep1 (encoding HCF-1 amino acids 867–1071)
containing the wild-type or E10A HCF-1pro repeat 1 was described in [9]. Deletions of Region
I (867–891), Region II (892–949), and Region III (850–1009) were obtained by QuickChange
site-directed mutagenesis (Agilent Technologies). The scrambled sequence of Region II was
generated by random permutation of the amino acids in Region II and the resulting oligonucle-
otide sequence with additional BamHI restriction sites at the 5’ and 3’ ends custom synthesized.
The fragments were PCR amplified and inserted into the pGEX-HCF-1rep1 vector using the
BamHI restriction sites. The mutations E10D, E10Q, E10S, T17–22A (Thr 17, Thr 19, Thr 21,
and Thr 22; see [9]), and ΔPRO (deletion of HCF-1 residues 1010–1035) in the HCF-1pro
repeat were engineered by QuickChange site-directed mutagenesis. The HCF-1rep1 trypsin
cleavage sites A933K and M951K for peptide generation in LC-MS/MS analysis were engi-
neered by site-directed mutagenesis.
For transient expression of the HCF-1rep1 deletion constructs in HEK 293 cells, a PCR frag-
ment encoding the GST–HCF-1rep1 sequence was amplified and inserted into a pCGN vector,
using XbaI and KpnI restriction sites. The sequence encoding the POUrep2 protein (Oct-1
sequence 280–439, in which the HCF-1PRO repeat 2 was embedded) was amplified from the
pET11c vector and inserted as a GST-fusion protein into the pCGN vector, using KpnI and
BamHI restriction sites. Constructs containing Regions II or III upstream of the HCF-1PRO
repeat were obtained by overlap extension PCR [43].
The bacterial expression plasmid pET24 containing N-terminal T7 and 8-His tags was
described in [44] and [22]. Site-directed mutagenesis was used as described above to generate
the D554H_H558D OGT mutant.
Cell culture and plasmid transfections
HEK 293 cells were grown on plates at 37°C in DMEM with 10% FBS. For plasmid transfec-
tion, 105 cells were seeded onto a 10 cm plate in 12 ml of DMEM with 10% FBS, and trans-
fected one and a half days after seeding with 4.8 μg of plasmid and 60 μl of Lipofectamine in
Opti-MEMmedium as described (Invitrogen).
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Bacterial protein expression
The recombinant HCF-1rep1 protein encoding HCF-1 amino acids 867–1071 and its mutants
were verified by sequencing. Proteins were synthesized in E. coli BL21 (DE3) as a fusion with
N-terminal GST and C-terminal 6-Hist tag and purified using Nickel affinity chromatography
according to the QIAexpressionist protocol (Qiagen) for native protein purification. Briefly, a
starter culture of BL21 (DE3) was grown for 6 h at 37°C. 100 ml Luria Bertani (LB) medium
containing 100 μg/ml carbenicillin was inoculated with 1 ml of starter culture and grown over
night at 22°C. Protein synthesis was induced the next morning with 0.4mM IPTG at 16°C for
6h to reduce the synthesis of C-terminal truncation products of the GST–fusion protein. The
bacterial pellet was resuspended in lysis buffer supplemented with Complete protease inhibitor
cocktail (Roche) and 0.1mg/ml lysozyme and incubated for 20 min on ice. The lysate was soni-
cated 12 times for 10 seconds, cleared at maximum speed for 30 min at 4°C, and incubated for
90 min at 4°C with Ni-NTA agarose superflow resin (Qiagen). The resin was washed three
times with wash buffer and eluted in 4 ml elution buffer. The proteins were concentrated in
Amicon concentration tubes (Milipore) and dialyzed against PBS supplemented with 1 mM
DTT overnight at 4°C. The concentrated dialyzed protein was frozen in liquid nitrogen and
stored at-70°C.
Recombinant human OGT was synthesized as a His-tag fusion protein in E. coli BL21
(DE3) cells as described in [22] with minor modifications: Bacterial cultures were grown in 200
ml volumes at 27°C after diluting an overnight culture 1 to 200 in fresh kanamycin supple-
mented LB media. Cells were grown to an OD600 of 1.1 and the temperature was lowered to
16°C for 30min. Protein expression was induced with 0.4mM IPTG at 16°C for 16h. The bacte-
rial pellet was resuspended in 20 ml lysis buffer (50 mM Tris pH 7.5, 150 mMNaCl, 0.1% Tri-
ton X-100, 10% glycerol) supplemented with Complete protease inhibitor cocktail (Roche) and
0.1mg/ml lysozyme final concentration and incubated for 30 min on ice. The lysate was then
sonicated 12 times for 10 sec to remove viscosity and ensure further lysis. The lysate was
cleared by high-speed centrifugation for 45 min at 4°C and incubated for 90 min at 4°C with
Ni-NTA agarose superflow resin (Qiagen). The flow-through was removed and the resin
washed with 3 column volumes PBS supplemented with 40mM imidazole. The protein was
then eluted in PBS supplemented with 250mM imidazole and the elute concentrated in Ami-
con concentration tubes (Milipore). The elute was dialyzed against PBS supplemented with 1
mMDTT overnight at 4°C. The concentrated dialyzed protein was supplemented with 1 mM
DTT and stored at-70°C.
HCF-1 cleavage andO-GlcNAcylation assays
In vitro HCF-1PRO-repeat cleavage and HCF-1 O-GlcNAcylation assays with bacterially syn-
thesized substrates and OGT were performed in 100 mMHEPES (pH 7.9), 5 mMMgCl2,
20 mM KCl, 5 mMDTT, and 10% sucrose at a final volume of 15 μl at 37°C for the indicated
time. For a typical assay, bacterially purified GST–HCF-1rep1 (3 μM; concentration measured
by comparative analysis with a protein loading control on Coomassie gel) was incubated with
bacterially purified OGT (0.6 μM, concentration measured as described above) in the presence
or absence of 1 mM UDP-GlcNAc and the reaction stopped by transfer of the tube to-20°C
and boiling in SDS-sample buffer. HCF-1 cleavage and O-GlcNAcylation were examined by
immunoblot.
In vivoHCF-1 cleavage assays were performed as follows: HEK 293 cells were transfected in
10 cm dishes with pCGN vectors encoding the HCF-1rep1 or POUrep2 precursor proteins as
described above. 48 hours after transfection, cells were washed in PBS and lysed in 0.5% NP40,
10 mM Tris-Cl (pH 8.0), 150 mM NaCl, 5 mMMgCl2 (NP40 buffer [45]) supplemented with
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Roche Complete protease inhibitors and 10 μg/ml Pefabloc SC (AEBSF from Roche Life Sci-
ence) final concentration for 20 min on ice. The lysate was cleared in a table centrifuge at maxi-
mum speed at 4°C for 20 min and incubated with 30 μl mouse α-HA-conjugated agarose beads
(Sigma) overnight at 4°C. Beads were washed four times in 0.5% NP40 buffer, and immunopre-
cipitated material was eluted in 5 bead volumes of HA-peptide (200 μg/ml), in order to avoid
elution of the IgG chains from the antibody conjugate, which would interfere with cleavage
band analysis by immunoblot. Samples were analyzed by immunoblot.
In vitro HCF-1–OGT binding assay
GST–HCF-1rep1–OGT pull-down assays were performed as in [22] with a few modifications:
Prior to the OGT pull-down, 20 μl of a slurry of α-T7 antibody-conjugated beads (polyclonal
from goat, Abcam) were incubated with PBS containing 5% (w/v) bovine serum albumin
(BSA) for 1 h at 4°C to decrease non-specific binding of GST–HCF-1rep1 to the agarose beads.
Subsequently, the beads were washed extensively in PBS. For the OGT pull-down, 2.5 μg
GST–HCF-1rep1 and 5 μg of OGT were pre-incubated in 0.5% NP40 buffer supplemented
with 5 mMDTT, in the presence or absence of 1 mMUDP-GlcNAc or UDP, in a rotating incu-
bator for 1 h at 20°C. After incubation, 9% of the reaction was removed as an input control for
the OGT pull-down. The washed α-T7 agarose beads were added to the reaction, the volume
increased to 500 μl using NP40 buffer and the suspension incubated for 1 h at 20°C. The beads
were centrifuged and subsequently washed in NP40 buffer at least three times for 5 min each
time at room temperature and the OGT–GST–HCF-1rep1 complexes eluted by boiling for
5 min in 20 μl of 2-fold SDS sample buffer. HCF-1rep1–OGT binding was subsequently ana-
lyzed by SDS-PAGE followed by immunoblot.
Immunoblot and antibodies
For immunoblot analysis, nitrocellulose membranes were incubated for 60 min with 5 ml of
LI-COR blocking buffer, followed by incubation with the relevant antibodies in 50% LI-COR
blocking buffer and 50% PBST (PBS containing 0.1% Tween 20), as described below, at 4°C
over night. The membranes were washed four times and incubated with the appropriate sec-
ondary antibodies (dilution 1:10,000) in 50% LI-COR blocking buffer and 50% PBST at room
temperature for 45 min. The membranes were extensively washed in PBS containing 0.5%
Tween20 and scanned with an Odyssey infrared imager (LI-COR).
Antibodies used to detect GST–HCF-1rep1, GST–POUrep2, O-GlcNAc and OGT were as
follows: rabbit polyclonal α-GST (1–109) (Santa Cruz) used at 1:1000, mouse monoclonal α-
HA-epitope (12CA5; [46]) used at 1:1000, mouse monoclonal (RL2) α-O-GlcNAc (Abcam)
used at 1:3000, mouse monoclonal α-T7 (Novagen) used at 1:5000.
Quantification of bands on immunoblots was performed using the LI-COR Image Quant
quantification software and visualized using GraphPad Prism version 6.0e.
Sample preparation forO-GlcNAcylation analysis by liquid
chromatography tandemmass spectrometry (LC-MS/MS)
Sample preparation for O-GlcNAcylation analysis by LC-MS/MS was performed as in [9] with
modifications. HA-tagged GST–HCF-1rep1 plasmid expression vectors with wild-type or with
E10A, E10D, E10Q, E10S, T17–22A, and ΔPRO mutated HCF-1PRO repeats were transfected
into eight 15 cm dishes of 293 cells for 48 hours. Cells were lysed in 8 ml NP40 buffer supple-
mented with 1mM PMSF, 10 μM PUGNAc and Roche Complete protease inhibitors. The
lysates were denatured by adding a final concentration of 1% SDS and incubation at 65°C for
10 min. The SDS concentration was adjusted to 0.1% by dilution with NP40 buffer, and lysates
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were incubated with α-HA agarose beads overnight at 4°C. Immunoprecipitated material was
eluted with HA-peptide as described above and the resulting elute concentrated using Amicon
concentration tubes (Milipore). For proteomic analysis, see below.
O-GlcNAcylation analysis by LC-MS/MS
For the O-GlcNAcylation analysis, purified proteins were resolved by SDS-PAGE and stained
with Coomassie Blue. Gel bands were excised from SDS-PAGE gel and in-gel digested with
sequencing-grade trypsin (Promega, Madison, WI, USA) as described [47, 48]. Extracted pep-
tides were then cleaved with Glu-C endoproteinase (Sigma-Aldrich, St. Louis, MO, USA).
Data-dependent LC-MS/MS analyses were carried out on a hybrid linear trap LTQ-Orbitrap
XL (Thermo Scientific) mass spectrometer interfaced to a nanocapillary HPLC equipped with
a C18 reversed-phase column (Thermo Scientific), using CID (collision induced dissociation)
mode for MS/MS fragmentation. MS/MS spectra were analyzed using Mascot 2.4 software
(Matrix Science, London, UK). Mascot was set up to search a custom-built database containing
the sequences of the HCF constructions and of contaminants (enzymes, keratins, etc.). Semi-
specific cleavage at K, R (not before P), and at E, D were used as the enzyme definition. Mascot
was searched with a fragment ion mass tolerance of 0.50 Da, a parent ion tolerance of 10 ppm,
and allowing two missed cleavages. Iodoacetamide and propionamide derivatives of cysteine,
deamidation of asparagine and glutamine, phosphorylation of serine and threonine, oxidation
of methionine, and addition of acetylhexosamine (HexNAc) to serine and threonine were spec-
ified in Mascot as variable modifications. O-HexNAc modified and phosphorylated residues
were considered confident if the ion score for the identified peptide was superior to 23 with a
site localization score (Mascot Delta Score) higher than 70% and potential if the ion score was
between 14 and 22 or localization score between 50 and 70%.
Molecular dynamics simulations
Molecular Dynamics (MD) simulations were performed using stochastic boundary conditions
(SBC) [49], after solvating the systems with a 24 Å radius sphere of TIP3P water molecules,
centered on the mutated residue. A 4 Å wide restrained buffer region, coupled to a heat bath
using the Langevin equation of motion and a 250 ps-1 friction constant [50], was used. Protein
atoms outside the buffer region were held fixed. The water molecules were kept within the
sphere by the use of a solvent boundary potential [51] and a friction constant of 62 ps-1 was
applied to the water oxygens [50]. After energy minimization, the system was gradually heated
and equilibrated at 300 K during 220 ps, while restraints initially applied on the heavy atoms
were progressively removed. The MD production run, during which all atoms in the reaction
region were unconstrained, was performed at 300 K for 2 ns. All molecular modeling calcula-
tions were performed starting from the high-quality crystal structure of the human OGT
bound to the peptide from HCF-1pro repeat 2 (1–26) E10Q and UDP-5SGlcNAc (PDB code
4N3B). This experimental structure was preferred to the lower-quality experimental structure
with E10 and UDP-GlcNAc (PDB code 4N3C) to perform molecular modeling calculations.
Before MD simulations, the 5S sulfur atom was replaced by an oxygen atom, while the Q10 res-
idue of the HCF-1pro repeat 2 was replaced by a E, D or A residue using the UCSF chimera
program.
For the calculation of residue contributions to the binding-free energy, the role of each resi-
due on the HCF-1–OGT binding free energy was estimated according to the MM-GBSA
approach [23, 24, 52], using the GB-MV2 implicit solvent model [53, 54]. This method allows
the decomposition of the total binding free energy into residue contributions. The contribution
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of each residue of interest was calculated and averaged over 500 frames regularly extracted
along a 2 ns SBCMD simulations centered on it.
Molecular graphics were performed with the UCSF Chimera visualization software [55].
Supporting Information
S1 Fig. Related to Fig 1. (A) Alanine scan of the HCF-1PRO-repeat residues P7–T14 in an in
vitro cleavage assay of HCF-1rep1 constructs. Cleavage was detected using α-GST antibodies.
Prominent (●) and faint (○) cleavage products are indicated. (B) In vitroHCF-1rep1–OGT
binding assay in the presence of UDP-GlcNAc. Detection of OGT and HCF-1rep1 was per-
formed using the indicated antibodies. Shown are 100% of OGT pull-down (panels a and b)
and 11% of the input (panels c and d). , IgG heavy chain. (C) In vitroHCF-1rep1–OGT bind-
ing assay in the presence of UDP. (Top) Gel loadings and antibodies used as described in (B).
(Bottom) Quantified HCF-1rep1 binding from the OGT-directed pull-down assay (top). Bands
were quantified from the immunoblot as ratio of OGT-bound HCF-1rep1 to total HCF-1rep1
in the assay. Obtained values are presented as log2 fold change relative to wild-type HCF-
1rep1–OGT binding. In (B) and (C), strong (●) and weak (○) OGT binding is indicated.
(TIF)
S2 Fig. Related to Fig 2. (A) Sequence conservation among vertebrate and invertebrate species
of the human HCF-1 sequences 867–1098. Six different vertebrate species where HCF-1 is
cleaved by OGT: Human, Mouse, Xenopus tropicalis, Xenopus leavis, Fugu rubripes and Danio
rerio were aligned with two invertebrate species where HCF is cleaved by Taspase1: Apis melli-
fera and Drosophila melanogaster, using the Jalview bioinformatics tool [26]. Residues are col-
ored in blue according to conservation following the Blosum62 score. Regions I, II, III, IV, and
the HCF-1PRO repeats 1 (rep1) and 2 (rep2) are indicated, and the residues were numbered
according to the human HCF-1 sequence. The black arrowheads indicate exon boundaries in
the human gene HCFC1 encoding HCF-1. (B) Schematic of the HCF-1rep1 full-length (FL)
construct (residues 867–1071) and the deletion constructs used in this study. Constructs ΔI,
ΔII, and ΔIII lack Regions I, II or III, respectively. ΔI.II.III and ΔI.II.III/E10A contain a deletion
of Regions I, II, and III together. Constructs +I, +II, and +III contain only Region I, II or III,
respectively, in addition to rep1 and the C-terminal, less-well conserved sequences of 36 amino
acids (Region IV). (C) In vivo cleavage activities (48 hours) of HCF-1rep1 deletion constructs
from three independent experiments (exp.1, exp. 2, exp. 3). 293 cells were transfected with
expression vectors encoding HCF-1rep1 FL or the deletion constructs depicted in (A). Synthe-
sized HCF-1rep1 proteins were immunoprecipitated by an N-terminal HA-tag and assayed for
cleavage by visualization and quantification of an α-HA tag immunoblot. Cleavage efficiencies
are given as ratios of cleaved product over total of uncleaved and cleaved HCF-1rep1 proteins.
(TIF)
S3 Fig. Related to Fig 4. Comparison of in vivo cleavage and O-GlcNAcylation activities (48
hours) between wild-type (WT) HCF-1rep1 and (A) HCF-1rep1 containing engineered trypsin
cleavage sites (A933K_M951K) or (B) HCF-1rep1 containing substitutions of the S984 phos-
phorylation site by alanine (S984A) and by aspartate (S984D), respectively. Cleavage (upper
panels) and O-GlcNAcylation (lower panels) were detected using the indicated antibodies. The
uncleaved precursors (–) and N-terminal cleavage products (●) are indicated.
(TIF)
S1 Table. Identification of O-GlcNAcylation and phosphorylation sites of the in vivo syn-
thesized uncleaved HCF-1rep1 protein and the N-terminal HCF-1rep1 cleavage product.
Residues in red and black are confident O-GlcNAcylation and phosphorylation sites (Mascot
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score> 23 & probability of localization> 70%) respectively, and residues in blue are potential
O-GlcNAcylation sites (Mascot score 14–22 or probability of localization 50–70%). N/A, not
applicable; N/D, not detected
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